Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Frontera London

- PMLiVE

Pfizer’s one-time haemophilia B gene therapy Durveqtix granted EC approval

More than 42,000 people globally are living with the rare bleeding disorder

- PMLiVE

AbbVie’s IL-23 inhibitor Skyrizi approved by EC to treat ulcerative colitis in adults

The form of inflammatory bowel disease is estimated to affect five million people globally

- PMLiVE

Ipsen gains ex-US rights to Day One’s brain cancer therapy in deal worth over $460m

Paediatric low-grade gliomas are the most common type of brain tumour diagnosed in children

- PMLiVE

Boehringer Ingelheim’s Metalyse recommended by NICE to treat stroke in adults

Ischaemic stroke is responsible for around 85% of all stroke cases in the UK

- PMLiVE

Bayer’s octopus move

The evolutionary lessons for Bayer’s management restructure

- PMLiVE

Danish Agency Twenty Launches New Campaign for F.C. Copenhagen and adidas That Gets International Attention

F.C. Copenhagen and adidas, in collaboration with the Danish agency Twenty, have launched the campaign 'FCK forever,' focusing on a significant health challenge. The campaign serves as a reminder for...

EatMoreFruit

- PMLiVE

Novartis and Dren Bio enter bispecific antibody partnership worth up to $3bn

The companies will aim to advance targeted myeloid engager programmes in oncology

- PMLiVE

Pfizer shares positive late-stage results for haemophilia A gene therapy

The rare bleeding disorder occurs in approximately 25 in every 100,000 male births globally

- PMLiVE

Ionis’ investigational antisense therapy shows promise in Angelman syndrome

ION582 is expected to enter late-stage development for the rare neurodevelopmental disorder in 2025

- PMLiVE

WHO calls for better medicines access to close neurological disorders treatment gap

In 2021, neurological conditions affected more than three billion people worldwide

- PMLiVE

ICR study on cell competition mechanism could lead to new ways of treating cancer

Female breast, lung, bowel and prostate cancers account for more than four in ten of all cancers worldwide

- PMLiVE

Enhancing participant payments: a new approach with IQVIA’s Participant Payments solution

IQVIA has developed a solution designed to simplify and streamline the payment process for all stakeholders involved in clinical trials

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links